Abstract
STATEMENT OF MY VIEW OF THE NATURE SIGNIF1CANCE OF THE WORK SUBMITTED
The publications attached to my thesis represent 19 years of research in fibrinolysis and haemostasis concentrating on their role in health and disease. They were written in collaboration with scientists and clinicians from the UK, various European countries, the USA, South America and Japan.
I started my research in 1974 by publishing new methods to help in the investigation of the different functions of fibrinolysis components in human plasma. We were the first group to apply radial-immuno diffusion and immuno-diffusion techniques to provide a simple and reliable assessment of the structural differences in related antigen structure of fibrinogen fragments (Ref. 1).
The new dimension of the techniques was used to investigate the fibrinogen evolution of living primates (Ref. 2). Other new and simple radio-immuno-metric assays were developed to measure components of human haemostasis in plasma with sensitive levels of detection (Ref. 5, 8, 9, 10, n ). These methods involve the competition between soluble and polyvinyl-immobilised antigen for monospecific antibody and labelled second antibody. The high sensitivity of these methods was useful in diagnosing disseminated intravascular coagulation, the so-called hyper coagulable state and incipient venous thrombosis.
To understand more about incipient venous thrombosis we investigated the characterisation of the breakdown of fibrinogen and fibrin clot in vivo (Ref 6, 7). As cross-linked fibrin is an important feature of most arterial and venous thrombi, we found that detection of specific soluble cross-linked fibrin degradation products in vivo could monitor pre-thrombotic state in man. We found that D-dimer fragment and other fibrin-cross-linked sub-units could be used as markers for the pre-thrombolytic and hyper coagulable state. Specific monoclon~ antibodies were developed (Ref. 14) to these circulating soluble cross-linked high molecular weight fibrin fragments in blood. These antibodies were used in assays which became an important tool in identifying the prethrombotic state. The results from these assays and production of the specific antibodies to soluble fibrin fragments attracted the attention of many clinicians to measure various soluble cross-linked fibrin molecules as an indicator for incipient thrombosis.
For better understanding of the role of fibrinolysis in haemostasis we investigated the role of fibrinogen and its degradation products in human platelets aggregation. We showed aggregation of human platelets by collagen in vivo to be influenced by the presence of fibrinogen with the extent of platelet aggregation decreasing progressively during the digestion of fibrinogen (Ref 3, 4).
To examine the balance between the haemostasis components, the role of anti-thrombin III as inhibitor of thrombin was examined (Ref. 12, 15). A tendency towards venous thrombosis was associated with a deficiency of anti-thrombin III. The early 1970s had seen increasing interest in the therapeutic use of A-III. In our investigation we examined the biological activities of A-III for clinical use from several manufacturers. Results showed some of these A-Ills to be unsuitable for clinical use because the heparin-binding site had been denatured during the purification process. As other factors besides thrombin and plasmin contribute to the balance of the haemostasis system, we investigated the role of calcium and chloride ions (Ref. 13 and 55). The result showed the formation of fibrin via the activation of thrombin to be dependant on the level of calcium ion in the blood. In reverse we found that chloride ion present in plasma could have a considerable effect on the activation of fibrinolysis via the activation of glu-plasminogen. Results proved circulating chloride to have an important role with the fibrinogen molecule in plasma in the use of tissue plasminogen activators as thrombolytic agents.
We studied the components in blood influencing the overall physiological fibrinolytic activity. We found that the three markers of predominant importance were tissue plasminogen activators (t-pA), plasminogen activator inhibitors, fibrinogen and fibrin degradation products. Our result showed that the role of the new inhibitor, called the specific fast-acting inhibitor, mayhave great influence on fibrinolysis. The data presented (Ref 17-20) suggest that the level of that inhibitor may be used as a reliable marker for the prethrombotic state. We also concluded that urokinase (UK), the other plasminogen activator, which is present in higher concentration thai1 tpA has no clear physiological role. The activation of plasminogen by its activators and the role of fibrinolytic inhibitors are responsible for fibrin destruction in vivo. the measurement of plasminogen activators and inhibitors with the level of soluble fibrin fragments is a reliable indicator of the role of fibrinolysis in disease. My contribution consisted of developing reliable assays to monitor these components (Ref. 17-20, 21, 29, 46, 50, 51). These assays are widely used in clinical fibrinolysis and by the World Health Organisation in the control and standardisation of fibrinolytic components. One of them is the Bio-immuno-assay which has been widely used in cancer research. It was published in 1984 (Ref. 17-19) and was later modified to be used for the plasminogen activator measurement in blood (Ref. 58, 76). For the first time this assay made it possible to measure the activity of fibrinolysis without the formation of euglobulin fraction. It allowed us to demonstrate that enhancement of the fibrinolytic system by exercise, venous occlusion ·and drugs were due to an increased level of t-pA rather than UK. This assay and its modifications helped us to understand the role of UK and t-pA in the haemostatic balance.
These assays are produced by various Biological Diagnostics companies as kits to explain clinical conditions associated with fibrinolysis and thrombotic events. The wide information from these assays encouraged clinicians in cancer research to use them for defining the role of fibrinolysis in cancer. we investigated the role of plasminogen activators and their inhibitors in malignant invasion in carcinoma and benign of the breast (Ref. 22-27 and 31, 32,33, 48, 53, 56, 65, 66, 73, 81, 84 ). Results showed that raised level of tissue fibrinolytic activity observed in certain malignant tissues may determine metastatic spread. The studies suggested that malignant transformation of breast is associated with the uninhibited and significantly increased production of urokinase which may be responsible for the characteristics of malignant growth. The work highlighted two hypotheses on the role of the fibrinolytic system in malignancy: 1. The high tissue activity promoted invasion, cell shedding and metastasis by removal of fibrin. 2. A low fibrinolytic activity allows the fibrin network to become established and to further metastic implantation.
The second investigation in cancer was in human colorectal cancer and gastric tumours (Ref. 34-45 and 52). The studies found that the generation of plasmin by plasminogen activators may play an important role in the regulating of the extracellular protease activity required for the transition from adenomatous polyp to invasive carcinoma. The enhanced capacity found in colorectal tumours to produce plasminogen activators and to generate plasmin is a feature of both the premalignant and the malignant phenotype. These enzymes may contribute to the malignant potential of adenomatous polyps and to the invasive capacity of established carcinomas. The investigations in breast and colorectal cancer highlighted the important role of pro-urokinase and urokinase plasminogen activators as important factors in malignant phenotype as well as the malignant potential of adenomatous polyps and invasive carcinoma. Our findings proved that ·t-pA was the important marker in blood, whilst urokinase was found to be an important determinant marker in malignant tissues (Ref. 81). These results were useful in explaining the relationship of plasminogen activators and oncagenes to tumour invasion (Ref. 79).
The role of plasminogen activators was also investigated in venous and Ischaemic leg ulcers (Ref. 67, 68, 69, 70, 71, 72, 75, 80, 85). The studies concluded that delayed wound healing in venous ulcers may be due to an excessive amount of plasmin leading to poor cellular adherence. Results showed that compared to the adjacent intact skin there was a significantly higher level of urokinase in the base and edges of the ulcer. Thus the plasminogen activator, urokinase, was found to be important in ulcer healing. The studies suggested that by manipulating the levels of urokinase one may affect cellular adherence and thus influence the rate of tissue healing.
One of my later and major contributions was on the measurement of t-pA function activity and specific activity. In the publications (Ref. 46, 57, 83) and in doc. 1 - 6 at Wellcome Research Laboratories I showed that when t-pA preparations used in thrombolytic therapy are compared in a variety of assays, the multi-functional nature of t-pA is not always expressed to the same extent. We demonstrate this problem by comparing natural isolated t-pA and t-pA secreted from Chinese hamster ovary (CHO) cells following genetic manipulation. Assay results suggested that genetically engineer~ t-pA and naturally produced t-pA were discretely different in structure. The findings from these investigations were presented for discussion to the International Committee for Thrombosis and Haemostasis. The Committee recommended that among the assays available for t-pA only the clot lysis assay reflects the physiological function of tissue plasminogen activity (see Doc. 1 and 3).
It is very nearly 19 years since I started my research in the field of Fibrinolysis and I feel that I have made a contribution to the clinical application of this field. I contributed in the finding of the overall markers of physiological fibrinolytic activity. I took part in the development of reliable assays to monitor the prethrombotic state in man. My group was among the first to show the important role of fibrinolysis in cancer. I have contributed in the standardisation and control of haemostasis components for the World Health Organisation and the International Committee for Thrombosis and Haemostasis and played an important role in the characterisation of genetically engineered tissue plasminogen activator as thrombolytic agent.
The publications attached to my thesis represent 19 years of research in fibrinolysis and haemostasis concentrating on their role in health and disease. They were written in collaboration with scientists and clinicians from the UK, various European countries, the USA, South America and Japan.
I started my research in 1974 by publishing new methods to help in the investigation of the different functions of fibrinolysis components in human plasma. We were the first group to apply radial-immuno diffusion and immuno-diffusion techniques to provide a simple and reliable assessment of the structural differences in related antigen structure of fibrinogen fragments (Ref. 1).
The new dimension of the techniques was used to investigate the fibrinogen evolution of living primates (Ref. 2). Other new and simple radio-immuno-metric assays were developed to measure components of human haemostasis in plasma with sensitive levels of detection (Ref. 5, 8, 9, 10, n ). These methods involve the competition between soluble and polyvinyl-immobilised antigen for monospecific antibody and labelled second antibody. The high sensitivity of these methods was useful in diagnosing disseminated intravascular coagulation, the so-called hyper coagulable state and incipient venous thrombosis.
To understand more about incipient venous thrombosis we investigated the characterisation of the breakdown of fibrinogen and fibrin clot in vivo (Ref 6, 7). As cross-linked fibrin is an important feature of most arterial and venous thrombi, we found that detection of specific soluble cross-linked fibrin degradation products in vivo could monitor pre-thrombotic state in man. We found that D-dimer fragment and other fibrin-cross-linked sub-units could be used as markers for the pre-thrombolytic and hyper coagulable state. Specific monoclon~ antibodies were developed (Ref. 14) to these circulating soluble cross-linked high molecular weight fibrin fragments in blood. These antibodies were used in assays which became an important tool in identifying the prethrombotic state. The results from these assays and production of the specific antibodies to soluble fibrin fragments attracted the attention of many clinicians to measure various soluble cross-linked fibrin molecules as an indicator for incipient thrombosis.
For better understanding of the role of fibrinolysis in haemostasis we investigated the role of fibrinogen and its degradation products in human platelets aggregation. We showed aggregation of human platelets by collagen in vivo to be influenced by the presence of fibrinogen with the extent of platelet aggregation decreasing progressively during the digestion of fibrinogen (Ref 3, 4).
To examine the balance between the haemostasis components, the role of anti-thrombin III as inhibitor of thrombin was examined (Ref. 12, 15). A tendency towards venous thrombosis was associated with a deficiency of anti-thrombin III. The early 1970s had seen increasing interest in the therapeutic use of A-III. In our investigation we examined the biological activities of A-III for clinical use from several manufacturers. Results showed some of these A-Ills to be unsuitable for clinical use because the heparin-binding site had been denatured during the purification process. As other factors besides thrombin and plasmin contribute to the balance of the haemostasis system, we investigated the role of calcium and chloride ions (Ref. 13 and 55). The result showed the formation of fibrin via the activation of thrombin to be dependant on the level of calcium ion in the blood. In reverse we found that chloride ion present in plasma could have a considerable effect on the activation of fibrinolysis via the activation of glu-plasminogen. Results proved circulating chloride to have an important role with the fibrinogen molecule in plasma in the use of tissue plasminogen activators as thrombolytic agents.
We studied the components in blood influencing the overall physiological fibrinolytic activity. We found that the three markers of predominant importance were tissue plasminogen activators (t-pA), plasminogen activator inhibitors, fibrinogen and fibrin degradation products. Our result showed that the role of the new inhibitor, called the specific fast-acting inhibitor, mayhave great influence on fibrinolysis. The data presented (Ref 17-20) suggest that the level of that inhibitor may be used as a reliable marker for the prethrombotic state. We also concluded that urokinase (UK), the other plasminogen activator, which is present in higher concentration thai1 tpA has no clear physiological role. The activation of plasminogen by its activators and the role of fibrinolytic inhibitors are responsible for fibrin destruction in vivo. the measurement of plasminogen activators and inhibitors with the level of soluble fibrin fragments is a reliable indicator of the role of fibrinolysis in disease. My contribution consisted of developing reliable assays to monitor these components (Ref. 17-20, 21, 29, 46, 50, 51). These assays are widely used in clinical fibrinolysis and by the World Health Organisation in the control and standardisation of fibrinolytic components. One of them is the Bio-immuno-assay which has been widely used in cancer research. It was published in 1984 (Ref. 17-19) and was later modified to be used for the plasminogen activator measurement in blood (Ref. 58, 76). For the first time this assay made it possible to measure the activity of fibrinolysis without the formation of euglobulin fraction. It allowed us to demonstrate that enhancement of the fibrinolytic system by exercise, venous occlusion ·and drugs were due to an increased level of t-pA rather than UK. This assay and its modifications helped us to understand the role of UK and t-pA in the haemostatic balance.
These assays are produced by various Biological Diagnostics companies as kits to explain clinical conditions associated with fibrinolysis and thrombotic events. The wide information from these assays encouraged clinicians in cancer research to use them for defining the role of fibrinolysis in cancer. we investigated the role of plasminogen activators and their inhibitors in malignant invasion in carcinoma and benign of the breast (Ref. 22-27 and 31, 32,33, 48, 53, 56, 65, 66, 73, 81, 84 ). Results showed that raised level of tissue fibrinolytic activity observed in certain malignant tissues may determine metastatic spread. The studies suggested that malignant transformation of breast is associated with the uninhibited and significantly increased production of urokinase which may be responsible for the characteristics of malignant growth. The work highlighted two hypotheses on the role of the fibrinolytic system in malignancy: 1. The high tissue activity promoted invasion, cell shedding and metastasis by removal of fibrin. 2. A low fibrinolytic activity allows the fibrin network to become established and to further metastic implantation.
The second investigation in cancer was in human colorectal cancer and gastric tumours (Ref. 34-45 and 52). The studies found that the generation of plasmin by plasminogen activators may play an important role in the regulating of the extracellular protease activity required for the transition from adenomatous polyp to invasive carcinoma. The enhanced capacity found in colorectal tumours to produce plasminogen activators and to generate plasmin is a feature of both the premalignant and the malignant phenotype. These enzymes may contribute to the malignant potential of adenomatous polyps and to the invasive capacity of established carcinomas. The investigations in breast and colorectal cancer highlighted the important role of pro-urokinase and urokinase plasminogen activators as important factors in malignant phenotype as well as the malignant potential of adenomatous polyps and invasive carcinoma. Our findings proved that ·t-pA was the important marker in blood, whilst urokinase was found to be an important determinant marker in malignant tissues (Ref. 81). These results were useful in explaining the relationship of plasminogen activators and oncagenes to tumour invasion (Ref. 79).
The role of plasminogen activators was also investigated in venous and Ischaemic leg ulcers (Ref. 67, 68, 69, 70, 71, 72, 75, 80, 85). The studies concluded that delayed wound healing in venous ulcers may be due to an excessive amount of plasmin leading to poor cellular adherence. Results showed that compared to the adjacent intact skin there was a significantly higher level of urokinase in the base and edges of the ulcer. Thus the plasminogen activator, urokinase, was found to be important in ulcer healing. The studies suggested that by manipulating the levels of urokinase one may affect cellular adherence and thus influence the rate of tissue healing.
One of my later and major contributions was on the measurement of t-pA function activity and specific activity. In the publications (Ref. 46, 57, 83) and in doc. 1 - 6 at Wellcome Research Laboratories I showed that when t-pA preparations used in thrombolytic therapy are compared in a variety of assays, the multi-functional nature of t-pA is not always expressed to the same extent. We demonstrate this problem by comparing natural isolated t-pA and t-pA secreted from Chinese hamster ovary (CHO) cells following genetic manipulation. Assay results suggested that genetically engineer~ t-pA and naturally produced t-pA were discretely different in structure. The findings from these investigations were presented for discussion to the International Committee for Thrombosis and Haemostasis. The Committee recommended that among the assays available for t-pA only the clot lysis assay reflects the physiological function of tissue plasminogen activity (see Doc. 1 and 3).
It is very nearly 19 years since I started my research in the field of Fibrinolysis and I feel that I have made a contribution to the clinical application of this field. I contributed in the finding of the overall markers of physiological fibrinolytic activity. I took part in the development of reliable assays to monitor the prethrombotic state in man. My group was among the first to show the important role of fibrinolysis in cancer. I have contributed in the standardisation and control of haemostasis components for the World Health Organisation and the International Committee for Thrombosis and Haemostasis and played an important role in the characterisation of genetically engineered tissue plasminogen activator as thrombolytic agent.
| Original language | English |
|---|---|
| Qualification | Professional Doctorate |
| Awarding Institution | |
| Supervisors/Advisors |
|
| Award date | 28 Feb 1994 |
| Publisher | |
| DOIs | |
| Publication status | Published - Feb 1994 |
| Externally published | Yes |
Bibliographical note
The thesis contains copyright material excluded from the version open to the publicUN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver